{
    "ticker": "DUSA",
    "name": "DUSA Pharmaceuticals, Inc.",
    "description": "DUSA Pharmaceuticals, Inc. is a biopharmaceutical company committed to developing and commercializing innovative therapeutic products for the treatment of dermatological conditions. Founded in 1991 and based in Wilmington, Massachusetts, DUSA focuses on utilizing its proprietary technology platform to enhance the efficacy of existing therapies and develop new solutions for unmet medical needs. One of the company's primary products is Levulan Kerastick, which is used in conjunction with blue light therapy to treat actinic keratosis, a precancerous skin condition. DUSA is dedicated to improving patient outcomes through advanced photodynamic therapy and continues to invest in clinical research and product development. The company's mission is to provide safe and effective treatments that improve the quality of life for patients suffering from skin diseases. DUSA is also exploring additional indications and applications for its technologies, aiming to expand its portfolio in the dermatology space and beyond, while adhering to the highest standards of safety and efficacy in its products.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Wilmington, Massachusetts, USA",
    "founded": "1991",
    "website": "https://www.dusapharma.com",
    "ceo": "Robert D. Burch",
    "social_media": {
        "twitter": "https://twitter.com/dusapharma",
        "linkedin": "https://www.linkedin.com/company/dusa-pharmaceuticals/"
    },
    "investor_relations": "https://www.dusapharma.com/investors",
    "key_executives": [
        {
            "name": "Robert D. Burch",
            "position": "CEO"
        },
        {
            "name": "Michael A. Mullen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Dermatological Products",
            "products": [
                "Levulan Kerastick"
            ]
        }
    ],
    "seo": {
        "meta_title": "DUSA Pharmaceuticals, Inc. | Innovative Dermatological Solutions",
        "meta_description": "Learn about DUSA Pharmaceuticals, Inc., a leader in dermatology innovation. Explore our therapeutic products and commitment to improving patient health.",
        "keywords": [
            "DUSA Pharmaceuticals",
            "Dermatology",
            "Actinic Keratosis",
            "Levulan",
            "Photodynamic Therapy"
        ]
    },
    "faq": [
        {
            "question": "What is DUSA Pharmaceuticals known for?",
            "answer": "DUSA Pharmaceuticals is known for its innovative dermatological products, particularly Levulan Kerastick for treating actinic keratosis."
        },
        {
            "question": "Who is the CEO of DUSA Pharmaceuticals?",
            "answer": "Robert D. Burch is the CEO of DUSA Pharmaceuticals, Inc."
        },
        {
            "question": "Where is DUSA Pharmaceuticals headquartered?",
            "answer": "DUSA Pharmaceuticals is headquartered in Wilmington, Massachusetts, USA."
        },
        {
            "question": "What are DUSA's main products?",
            "answer": "DUSA's main product is Levulan Kerastick, used for photodynamic therapy in dermatology."
        },
        {
            "question": "When was DUSA Pharmaceuticals founded?",
            "answer": "DUSA Pharmaceuticals was founded in 1991."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "GILD",
        "REGN"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "ABBV"
    ]
}